Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multi-state battle to stop sales of replica ...

Eli Lilly and Company LLY will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus ...

Eli Lilly and Company (NYSE: LLY) is one of the stocks in focus in the game plan Jim Cramer shared. Cramer noted that the ...

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

That opens the door for broader access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss. Demand for the injection has soared over the last year ...

Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market ...

Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager ...

People who are in need of weight loss medications but do not have insurance coverage will soon have a new way to access one of the popular medications, Zepbound. Eli Lilly, the maker of Zepbound, ...

BDF-GESTION sold 4,149 shares of Eli Lilly ( LLY 0.58%) stock during the quarter. The estimated transaction value was $3.09 million, using the average unadjusted closing price for the quarter. After ...